Iovance Biotherapeutics, Inc. stock faces challenges with disappointing Q1 earnings and competition. Click for why potential ...

Analysts are intrested in these 5 stocks: ( ($O) ), ( ($GTLB) ), ( ($DASH) ), ( ($IOVA) ) and ( ($SENS) ). Here is a breakdown of their recent ...

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...

Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

NEW YORK CITY, NY / ACCESS Newswire / July 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ ...

Iovance Biotherapeutics (IOVA) has appointed Corleen Roche as chief financial officer, effective August 6th, 2025. IOVA -5.97% premarket to $1.89. Source: Press ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.